| pubmed-article:15743210 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15743210 | lifeskim:mentions | umls-concept:C0064239 | lld:lifeskim |
| pubmed-article:15743210 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:15743210 | lifeskim:mentions | umls-concept:C0231491 | lld:lifeskim |
| pubmed-article:15743210 | lifeskim:mentions | umls-concept:C0205164 | lld:lifeskim |
| pubmed-article:15743210 | lifeskim:mentions | umls-concept:C0068961 | lld:lifeskim |
| pubmed-article:15743210 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:15743210 | pubmed:dateCreated | 2005-3-3 | lld:pubmed |
| pubmed-article:15743210 | pubmed:abstractText | Indolic N-benzylation of naltrindole reportedly extends the duration of delta-opioid receptor (DOR) antagonism. Similar modification of the kappa-opioid receptor (KOR) antagonist norBNI (1a) and its 17,17'-diNMe analogue (1d), a low potency mu-opioid receptor (MOR) partial agonist, was found to affect predominantly their MOR activity. When administered systemically in mouse antinociceptive assays, N-benzyl-norBNI (1b) had only MOR agonist activity of relatively short duration whereas on central administration it had only a KOR-antagonist action of extremely long duration. | lld:pubmed |
| pubmed-article:15743210 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15743210 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15743210 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15743210 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15743210 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15743210 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15743210 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15743210 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15743210 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15743210 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15743210 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15743210 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15743210 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15743210 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:15743210 | pubmed:issn | 0022-2623 | lld:pubmed |
| pubmed-article:15743210 | pubmed:author | pubmed-author:SrivastavaSan... | lld:pubmed |
| pubmed-article:15743210 | pubmed:author | pubmed-author:TraynorJohn... | lld:pubmed |
| pubmed-article:15743210 | pubmed:author | pubmed-author:HusbandsSteph... | lld:pubmed |
| pubmed-article:15743210 | pubmed:author | pubmed-author:MillerCarl... | lld:pubmed |
| pubmed-article:15743210 | pubmed:author | pubmed-author:LewisJohn WJW | lld:pubmed |
| pubmed-article:15743210 | pubmed:author | pubmed-author:ChauvignacCéd... | lld:pubmed |
| pubmed-article:15743210 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15743210 | pubmed:day | 10 | lld:pubmed |
| pubmed-article:15743210 | pubmed:volume | 48 | lld:pubmed |
| pubmed-article:15743210 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15743210 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15743210 | pubmed:pagination | 1676-9 | lld:pubmed |
| pubmed-article:15743210 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:15743210 | pubmed:meshHeading | pubmed-meshheading:15743210... | lld:pubmed |
| pubmed-article:15743210 | pubmed:meshHeading | pubmed-meshheading:15743210... | lld:pubmed |
| pubmed-article:15743210 | pubmed:meshHeading | pubmed-meshheading:15743210... | lld:pubmed |
| pubmed-article:15743210 | pubmed:meshHeading | pubmed-meshheading:15743210... | lld:pubmed |
| pubmed-article:15743210 | pubmed:meshHeading | pubmed-meshheading:15743210... | lld:pubmed |
| pubmed-article:15743210 | pubmed:meshHeading | pubmed-meshheading:15743210... | lld:pubmed |
| pubmed-article:15743210 | pubmed:meshHeading | pubmed-meshheading:15743210... | lld:pubmed |
| pubmed-article:15743210 | pubmed:meshHeading | pubmed-meshheading:15743210... | lld:pubmed |
| pubmed-article:15743210 | pubmed:meshHeading | pubmed-meshheading:15743210... | lld:pubmed |
| pubmed-article:15743210 | pubmed:meshHeading | pubmed-meshheading:15743210... | lld:pubmed |
| pubmed-article:15743210 | pubmed:meshHeading | pubmed-meshheading:15743210... | lld:pubmed |
| pubmed-article:15743210 | pubmed:meshHeading | pubmed-meshheading:15743210... | lld:pubmed |
| pubmed-article:15743210 | pubmed:meshHeading | pubmed-meshheading:15743210... | lld:pubmed |
| pubmed-article:15743210 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:15743210 | pubmed:articleTitle | Major effect of pyrrolic N-benzylation in norbinaltorphimine, the selective kappa-opioid receptor antagonist. | lld:pubmed |
| pubmed-article:15743210 | pubmed:affiliation | Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, UK. | lld:pubmed |
| pubmed-article:15743210 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15743210 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:15743210 | lld:chembl |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15743210 | lld:pubmed |
